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Hepatocyte growth factor is a plasminogen-like molecule with diverse biological effects. Although it is synthesized as a single chain polypeptide, 
it was originally purified as a disulfide-linked heterodimer which was generated by an internal proteolyti¢ event. Subsequent work indicated that 
preparations consisting largely of the monomerie form also exhibited potent activity. By using a combination ofprotease inhibition and site-dlrected 
mutagenesis+ we established that conversion of the single chain polypeptide to the heterodimer occurred uring the bioassay and was required for 
mitogenic and motogenie activity. 
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1. INTRODUCTION 
Hepatocyte growth factor (HGF) was initially identi- 
fied as a mitogen for hepatoc2/tes [1-5], but subse- 
quently was shown to stimulate the proliferation of a 
variety of cell types, including melanocytes, vascular 
endothelial cells and epithelial cells derived from many 
different organs [6-I1]. It also has been reported to 
exhibit a eytotoxie ffect on selected tumor cell lines 
[12]. HGF is indistinguishable from scatter factor (SF) 
[13-15], a motility agent that stimulates the dispersion 
of certain epithelial and endothelial cells [16-19]. Re- 
cently, branching morphogenesis fi'om cysts of' MDCK 
(Madin-Darby canine kidney) cells grown in collagen 
gels was attributed to HGF/SF [20]. The c-met proto- 
oncogene product, a membrane-spanning tyrosine ki- 
nase [21-23]. is a high-affinity HGF/SF receptor [24°25], 
presumably involved in malay, if not all+ of these activi- 
ties. 
Structurally, HGF/SF resembles plasminogen i that 
they share a 38% identity in amino acid sequence and 
both are comprised of kringles [26] and a serine-pro- 
tease domain. However, HGF/SF lacks two of the three 
residues which form the catalytic triad and, conse- 
quently, is thought o be devoid of proteolytic activity 
[27]. Molecular cloning revealed that HGF/SF, like 
plasminogen, is synthesized as a single chain polypep- 
tide (p87) which can be cleaved to generate a disulfide- 
linked heterodimer consisting of a heavy (¢z, p60) and 
light (fl, p32-34) chain [27,28]. Although HGF/SF was 
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originally purified as a biologically active heterodimer 
[2-4], preparations consisting largely of the p87 mono- 
mer also exhibited potent mitogenic activity [6,29]. 
Thus, either the single chain form possessed intrinsic 
activity or its processing to the biologically active h ter- 
odimer occurred uring the bioassay. If processing was 
required for biological activity, it might be an important 
mechanism for the regulation of HGF/SF function. To 
address this issue, we employed protease inhibition, as 
well as site-directed mutagenesis, and established that 
conversion to the heterodimer is necessary for mito- 
genie and scattering activity. 
2. EXPERIMENTAL 
2.1. Site-dfrected mutagenesis 
The HGF/SF cleavage mutants were generated using a two-step 
PCR method [30] to modify the R494 codon, In the first step. two 
reactions were performed inparallel using as template a pCDV expres- 
sion vector containing the entire HGF/$F ending sequence (nueleo- 
tides -27 to 2,199, according to the numbering scheme in [28]) [6] and 
the following primers: (i) a (÷)primer spanning the wild-t),pe ~equeace, 
456~79 (5'.GAGTTCCATGATACCACACGAACA-3') was cou- 
pled with a (-)primer corresponding to sequence 1,496-1,473 in which 
the R494 eodon was substituted either with a K494 eodon (5'- 
ATCCCATTTACAACC'I~CAA'I'I'GT.3'I or E494 ¢odon (5'- 
ATCCCATTTACAACCTGCAATTGT-3'); (ii) a (+)primer span- 
ning the sequence+ 1.473-1,496. in which the R494 eoaoa was sub- 
stituted either with a K494 eodon(5'-ACAATTGAAGG'I'FGT- 
AAATGGGAT-3') or a E494 codon (5'-ACAATTGCAGGTT- 
GTAAATGGGAT-3') was coupled with a (-)primer corresponding 
to wild-type sequence, 2,112-2.089 (5"-ACCAGGACGA'ITfGGA- 
ATGGCACA-3'). PCR was performed for 25 cycles under low strin- 
gency conditions: 94°C, 1 rain; 37°C. 2 rain; 72°C, 3 rain, The desired 
reaction products. 1.04 and 0.64 kb, respectively, were purified by 
agarc~e gel etectrophore.~is. 
These product-~ were u~,-~l az the templates for a subsequent reaction 
using a (+)primer spanning the wild-type sequence, 658-687 
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(5'-CGAGGTCTCATGGATCATACAGAATCAGGC.3')  and a 
(-)primer corresponding to wild-type sequence, 1,874-1,857 (5'-AT- 
AGTTGATCAATCCAGT-Y). PCR was carried out for 35 cycles 
under the following conditions: 94°C, 1 s in:  60°C, 2 sin; 72°C, 3 
mln. The 1.21 kb product of tiffs reaction was recovered from an 
agarose gel and digested with Bglll to excise a 0.5 kb fragment con. 
taining the mutated sequence. This I'ra~ment was ligated into the 
original pCDV-HGF/SF construct from which the corresponding 
Bglll fragment had been removed. The pCDV-HGF/SF mutant con- 
struets were transformed in DH5 F'IQ competent bacteria (GIbco- 
BRL) and the sequence of the region between the two Bgtll sites was 
confirmed by nucleotide sequence analysis [31]. 
2.2. Recombinant expression 
Transient expression of  the wild-type and mutant HGF/SF proteins 
was carried out with COS-I cells as previously described [6]. The 
conditioned medium wa-~ concentrated around 25-fold in a Centricon. 
30 mieroeoneentrator (Amieon) prior to testing in the mitogenie or 
scatter bioassays. 
2,3, Bios!,t+rhetie studies 
Metabolic labeling and immunopreeiphation were performed as 
previously described [6] with a few modifications. Translbeted COS-I 
cells were incubated with eysteine-free, serum.free DMEM for 1 h 
prior to labeling with [}~S]cysteine (1 mCi/5 ml per dish. New England 
Nuclear) for 12 h. In some instances 0.1% fetal bovine serum was 
prc+ent during the labeling period. After the labeled medium was 
concentrated >10,fold in Centricon-30 m ieroconcentrators, protein 
~as immunoprecipitated with 10/.tg of preimmune or immune antise- 
rum raised against highly purified HOF/SF [6]. The samples were 
analyzed by autoradio~,raph~, of gels dried Ibllowing SDS/10% PAGE 
under reducing conditions [32l. 
2.4. Plasm#+ treatment of ftGF/SF 
Approximately 15 pl of concentrated medium co,,raining wild.type 
HGF/SF generated in the absence orserum was incubated with human 
plasmin (0.15 U/ml, American Diagnostiea) in DMEM containing 0.1 
i'M HEPES, pH 7.4 (total reaction volume, 100/el) for 1 h at 37°C. 
2+5. Assays of HGF/SF biological activio, 
DNA synthesis by B5/589 human mamma,'y epithelial cells was 
measured by [+H]thymidine incorporation as described [33,34]. 
The scatter assay was performed according to published methods 
[ 16]. After 20 h, the ceils were fixed for 20 s in  with 0.1 ml of methanol/ 
formaldcltyde/phosphate-buffered saline (7/2/1) and stained with he- 
rnatoxylin and rosin. 
APROTININ 
40000 '  
~ " 30000 





" ' i  
..; .: .~.! 
+~++++ 
:~+ , :." +:. +,'.~,, 




_T_ , . . . . .  ~ l 
:::(:?i:i :- = • . . : . :  ... 
. . . .  • ... ,. 
.... . . . . . .  ~, .:~ 
iiiii::!i  : ; ' .~ ,5~,  " • .+c¢ .~ • 
. ~ .v  , : '~ .< i " : . ,~ ~, +~;~. 
PLASMIN-TREATED 
HGFISF. 
Fig. 1. Eff~t ofaprotinin on DNA synthesis of B5/589 eellsstimulated 
by unprocessed vs. plasmin-treated HGF/SF. Equal volumes of con- 
centrated media were added to-bioassay wells after a 1 h pre-ineuba. 
tion with (+) or without (-) aprotlnin (100 trypsin U/el; bovine lun~ 
aprotinin, Boehringer-Mannheim). Mean cpm _ S.D. or triplicate 
measurements are presented. Background with untreated cells was 
,-,, 3,000 cpm; all mitogenic activity in the recombinant preparations 
could be neutralized by antiserum against HGF/SF [6]. *S.D. was too 
small to be shown on histogram. 
hibit the mitogenic action of epidermal growth factor 
(data not shown), arguing against a toxic effect. To 
ensure that he inhibitory effect of aprotinin on the 
activity of p87 was due specifically to inhibition of 
HGF/SF processing, the assay was carried out in paral- 
lel with a portion of the same recombinant preparation 
previously treated with plasmin to generate the hetero- 
dimer before addition to the bioassay. The plasmin- 
treated sample stimulated a high level of DNA synthesis 
comparable to that of unprocessed HGF/SF but was 
not inhibited by aprotinin (Fig. 1). This implied that the 
serine protease inhibitor reduced the activity or the sin- 
gle chain form of HGF/SF by disrupting its conversion 
to the heterodimer in the mitogenic bioassay. 
3, RESULTS 
3.1, Serine protease hzhibitor blocks HGF/SF mitogenic 
activity 
HGF/SF secreted by COS cells, transiently express- 
ing the full-length coding sequence, exhibited potent 
activity in a [3H]thymidine incorporation assay using 
quiescent B5/589 human mammary epithelial cells (Fig. 
1). For these experiments, the growth factor was pre- 
pared such that it was predominantly in the single chain 
form, p87 (see Fig. 2, left panel). To determine whether 
the mitogenic activity was a direct effect of p87 itself or 
a consequence of proteolytie processing to the hetero- 
dimeric form, the bioassay was also performed in the 
presence of the serine protease inhibitor, aprotinin. As 
shown in Fig. 1, thymidine incorporation was signifi- 
cantly reduced when aprotinin was included in the 
assay. Under the same conditions aprotinin did not in- 
3.2. Biochemical analysis of wild-type and mutant HGF/ 
SF molecules 
To confirm the hypothesis that internal cleavage of 
p87 was required for its biological activity, we prepared 
two mutants with alterations at the putative cleavage 
site. In both instances the arginine residue at position 
494 was replaced, either conservatively with lysine 
(R494K) o1" non-conservatively with glutamic acid 
(R494E). The wild-type and mutant forms were ex- 
pressed transiently in COS-1 cells metabolically labelled 
with [~sS]cysteine. The recombinant proteins were re- 
covered from conditioned medium by immunopreeipi- 
tation with HGF/SF antiserum and visualized by au- 
toradiography following SDS/PAGE. Similar levels of 
labeled protein were obtained following transfection 
with the three different constructs (Fig 2). Cells trans- 
fected with the wild-type sequence in the anti-sense ori- 
entation did not produce any protein specifically recog- 
18 





















TYPE R494K R494E 'rYPE-A 
I 1 I I t I I I 
~ . - . .  ~ ,  - ?~ . .  
41b  
=, 
PI PI I PI 1 PI I PI 1 PI 1 PI | Pl I 
Fi~. 2. Processing of HGF/SF  wild-type and cleavage mutants in the absence or presence of0.1% fetal bovine serum. Metabolically labeled protein 
from COS-I tran~lbctants was precipitated with preimmune (Pl) or immune (I) serum and resolved by SDS/PAGE. Results from cells transfected 
with the wild.type sequence in the antl-sense orientation (WILD TYPE-AS) are also provided. Arrows indicate monomeric HGF/SF (p87) as well 
as the heavy (:r) and light (fl) chains of the heterodimer. The light chain fi'equently has been observed as a doublet [3,6,18]. Molecular mass markers 
are indicated (in kDa). 
nized by the HGF/SF antiserum. With each of the other 
constructs, cells labeled in serum-free medium exhibited 
little or no evidence of HGF/SF processing. On the 
other hand, use of serum.containing medium during the 
labeling period resulted in conversion of most of the 
wild-type and R494K protein to the heterodimeric form 
(Fig. 2). In contrast, the R494E protein remained un- 
processed, which indicated that this mutant cottld be 
used to test the requirement of proteolytic processing 
for biological activity. 
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Fig. 3. Mitogenic stimulation by HGF/SF  wild-type and cleavage 
variants of quiescent B5/589 mammary epithelial cells. Data fi'om a 
representative xperintent arc presented as the mean cpm of duplicate 
measurements that varied <3,000 cpm. 
3.3. Biological acth,ity of the site-directed mutants 
When the mitogenic activity of wild-type and variant 
HGF/SF proteins was compared in the B5/589 bioas- 
say, dramatic differences were observed. While the 
R494K derivative was slightly less potent than the na- 
tive molecule, the R494E protein failed to stimulate 
DNA synthesis at any of the concentrations tested (Fig. 
3). This was the case despite the fact that similar 
amounts of immunologically cross.reactive proteins 
were present in the samples ( data not shown). Further- 
more, comparable results were obtained when the vari- 
ous HGF/SF analogs were monitored for their ability 
to induce scattering of the MDCK cells. Both the wild- 
type and R494K proteins stimulated the characteristic 
spreading and dispersion of cells associated with a fi- 
broblastoid phenotype. In contrast, the R494E variant 
was devoid of such activity (Fig. 4). These differences 
in biological activity were not attributable to gross 
structural changes, as judged by similar heparin-bind- 
ing properties (unpublished observations) and immu- 
nological cross-reactivity of the proteins (Fig. 2). Thus, 
these findings established that inhibition of HGF/SF 
conversion to the heterodimerie form eliminated both 
mitogenic and scattering activity. 
4. D ISCUSSION 
In the present study we demonstrated that a aprot- 
inin~ a serine protease inhibitor, specifically blocged the 
ability of HGF/SF pS7 to stimulate DNA synthesis in 
B5/589 cells, which provided strong evidence that proc- 
19 
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Fig, 4. Eff~t of HGF/$F wild-tYl~ and cleavage mutants in scatter assay with MDCK cells. Photomicrographs of cells treated with a I' 2'7:,0 dilution 
of concentrated, conditioned medium containing similar quantities of wild-type HGF/SF (A), R494K (B), R494E (C) or no adaition (D). 
Magnification ×400. These pictures are representative of the fields in multiple wells a,~d reflect consistent differences inserial dilutions oi' the samples. 
essing occurred uring the bioassay and was required 
for mitogenesis. The persistence of some growth factor 
activity in this experiment was presumably due to in- 
complete inhibition of the endogenous protease(s). To 
confirm this interpretation, we prevented proteolytic 
cleavage entirely by site-directed mutagenesis of the 
cleavage site. The non-conservative substitution of glu- 
ramie acid for arginine 494 rendered the molecule resis- 
tant to processing without altering other physical attrib- 
utes, as indicated by its binding both to heparin and a 
specific HGF/SF antiserum. We further showed that 
this analog was totally lacking in mitogenic and scatter- 
ing activity. Thus, we conclude that an internal cleavage 
step is required for HGF/SF biological activity. 
The location and identity of the pretense(s) responsi- 
ble for processing are unknown, but existing data offer 
some basis for speculation. Because the factor is readily 
secreted in the monomeric form, cleavage presumably 
occurs outside the cells producing HGF/SF. The fact 
that processing takes place in our bioassays implies that 
the active protease(s) may reside on the target cell's 
surface or in its extracellular matrix. Insofar as the cells 
in our bioassays are routinely exposed to serum prior 
to testing, either serum nor the ceils could be the source 
of a converting enzyme. Preliminary efforts to repro- 
dace the cleavage event in a cell-free system suggest that 
neither serum nor plasminogen activators, pretenses 
commonly associated with the cell surface and extracel- 
lular matrix [35,36], are solely capable of HGF/SF proc- 
essing (unpublished observations). Nonetheless, the 
plasmin/plasminogen activator system is an attractive 
candidate for HGF/SF activation. The structural ho- 
mology of HGF/SF and plasminogen extends to their 
internal cleavage site [27], raising the possibility of a 
common processing mechanism. Even if the plasmino- 
gen activators are not directly responsible for the proc- 
essing of HGF/SF, they might activate cell-associated 
plasminogen absorbed from serum (or the bloodstream 
in rive) which in turn could cleave the HGF/SF precur- 
sor, just as plasmin mediates the processing of latent 
TGF-fl in fibroblast culture fluid [37]. The coordinated 
activation of plasminogen and HGF/SF in the context 
of cell proliferation, migration or tissue remodelling is
a compelling scenario which warrants further investiga- 
tion. 
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